6505--Lab Supplies-Radiopharm |Consolidating 595, 642, 646 5 Year Indefinite Delivery/Indefinite Quantity (IDIQ) Radiopharmaceuticals |Xofigo, Illuccix, NETSPOT |

SOL #: 36C24426Q0298Special NoticeSole Source

Overview

Buyer

Veterans Affairs
Veterans Affairs, Department Of
244-NETWORK CONTRACT OFFICE 4 (36C244)
PITTSBURGH, PA, 15215, United States

Place of Performance

Place of performance not available

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Timeline

1
Posted
Feb 11, 2026
2
Action Date
Feb 13, 2026, 3:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Department of Veterans Affairs (VA), Network Contracting Office 4 (NCO4), has issued a Special Notice of Intent to Sole Source a consolidated five-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Cardinal Health, 414, LLC. The requirement is for the delivery and inventory management of specific name-brand radiopharmaceuticals—Xofigo, Illuccix, and NETSPOT—for the Lebanon, Philadelphia, and Pittsburgh VA Medical Centers. Capability statements are due by February 13, 2026.

Scope of Work

The contractor will provide timely delivery and continuous inventory management for the following name-brand agents:

  • Xofigo (Radium 223 dichloride): Used for castration-resistant prostate cancer with bone metastases.
  • Illuccix (Gallium 68 PSMA-11): A PET imaging tracer for detecting prostate cancer cells.
  • NETSPOT (Gallium 68 Dotatate): A PET tracer for neuroendocrine tumor diagnosis.

Key Requirements:

  • Geographic Proximity: Due to the 68-minute half-life of these radiopharmaceuticals, the distributor must be located within the Pittsburgh, Philadelphia, and Lebanon areas.
  • Licensing: Must hold current NRC and FDA licenses for producing and distributing radiopharmaceuticals.
  • Technical Standards: Products must be barcode-labeled for compatibility with the VA’s Nuclear Medicine Information System (NMIS). Non-High Enriched Uranium (non-HEU) sources are preferred.
  • Logistics: Includes quality control testing, hazardous material transport, and disposal of used/unused items.

Contract & Timeline

  • Type: Firm-Fixed-Price IDIQ
  • Duration: Five years (April 1, 2026 – March 31, 2031)
  • Set-Aside: None (Intent to Sole Source to Cardinal Health)
  • Response Due: February 13, 2026, at 10:00 AM EST

Evaluation

While the VA intends to sole source this requirement under FAR 6.103-11, it will evaluate capability statements to determine if a competitive procurement is in the government's best interest. If no viable responses are received, the VA will proceed with Cardinal Health.

Additional Notes

Interested vendors must submit a one-page capability statement including their UEI number, socioeconomic category, and a description of their ability to service all three specified VA locations.

People

Points of Contact

Christa StineContract SpecialistPRIMARY

Files

Files

Download

Versions

Version 1Viewing
Special Notice
Posted: Feb 11, 2026
6505--Lab Supplies-Radiopharm |Consolidating 595, 642, 646 5 Year Indefinite Delivery/Indefinite Quantity (IDIQ) Radiopharmaceuticals |Xofigo, Illuccix, NETSPOT | | GovScope